Nutriband (NTRB) vs OS Therapies (OSTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
OS Therapies (OSTX) has outperformed Nutriband (NTRB) over the past year, losing 20.6% versus a loss of 28.8%. Nutriband is the larger company by market cap ($80.2 million vs $75.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NTRB | OSTX |
|---|---|---|
| Share price | $6.60 | $1.62 |
| Market cap | $80.23M | $75.82M |
| 1-day change | +9.09% | 0.00% |
| YTD return | +33.26% | +15.71% |
| 1-year return | -28.82% | -20.59% |
| 5-year return | -11.15% | — |
| Forward P/E | — | 4.67 |
| EPS (TTM) | $-0.53 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.19 | $2.25 |
| 52-week low | $2.80 | $1.15 |
| Distance from 52-week high | -28.14% | -28.00% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +127.27% | +424.69% |
| Average volume | 62.42K | 586.70K |
| Shares outstanding | 12.16M | 46.81M |
| Employees | — | 4 |
| Sector | Health Care | Health Care |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Nutriband
NTRB stock →Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States.
Health Care · Industrial Specialties
About OS Therapies
OSTX stock →OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
NTRB vs OSTX FAQ
Which is bigger, Nutriband or OS Therapies?
Nutriband (NTRB) is larger, with a market capitalization of $80.23M compared with $75.82M for OS Therapies (OSTX).
Which stock has performed better over the past year, NTRB or OSTX?
OSTX returned -20.59% over the past 12 months, compared with -28.82% for NTRB (price return, excluding dividends). Past performance does not predict future results.
Are Nutriband and OS Therapies in the same industry?
Both are in the Health Care sector, but in different industries: Industrial Specialties for Nutriband and Biotechnology: Pharmaceutical Preparations for OS Therapies.